Loading company…
Viracta Therapeutics develops treatments for virus-related cancers and other serious diseases.
Founded in 2007 and based in California, US, Viracta Therapeutics focuses on precision oncology for virus-related diseases. Its investigational approach combines nanatinostat with valganciclovir to target EBV-positive lymphoma, with research into other EBV-related and virus-related cancers. In 2020, Sunesis Pharmaceuticals merged with Viracta; Viracta raised USD 65 million in PIPE funding in February 2021, led by BVF Partners.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in